ASCO Proceedings. Clinical and molecular features of long-term response to anti-PD-(L) 1 therapy in patients with advanced non-small cell lung cancer. 2023.
ASCO Proceedings. Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT carcinoma registry. 2023.
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 May 27.
View in:
PubMed
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 Jul; 34(7):589-604.
View in:
PubMed
Thoracic Malignancies. Pocket oncology. Third edition / edited by Drilon, A. Vasan, N, Choudhury, N, Murciano-Goroff, YR. 2022.
Phase I trial of the TNF-a inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022 10 15; 13(1):6095.
View in:
PubMed
Safety of image guided research biopsies in patients with thoracic malignancies. Lung Cancer. 2022 11; 173:53-57.
View in:
PubMed
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 10; 3(10):1151-1164.
View in:
PubMed
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040.
View in:
PubMed
Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022 08; 33(8):824-835.
View in:
PubMed
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328.
View in:
PubMed
Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11.
View in:
PubMed
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764.
View in:
PubMed
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140.
View in:
PubMed
Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiother Oncol. 2021 08; 161:115-117.
View in:
PubMed
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 02; 9(2).
View in:
PubMed
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5.
View in:
PubMed
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discov. 2021 01; 11(1):59-67.
View in:
PubMed
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 12; 10(12):1842-1853.
View in:
PubMed
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2).
View in:
PubMed
COVID-19 in patients with lung cancer. Ann Oncol. 2020 10; 31(10):1386-1396.
View in:
PubMed
MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 09; 17(9):569-587.
View in:
PubMed
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 08; 10(8):1121-1128.
View in:
PubMed
Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12.
View in:
PubMed
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020 06 15; 26(12):2849-2858.
View in:
PubMed
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311.
View in:
PubMed
Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. Clin Breast Cancer. 2018 12; 18(6):498-503.
View in:
PubMed
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151.
View in:
PubMed
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol. 2016; 8:217-224.
View in:
PubMed
Current Patterns of Care for Patients with Extensive-Stage SCLC: Survey of U.S. Radiation Oncologists on Their Recommendations Regarding Prophylactic Cranial Irradiation. J Thorac Oncol. 2016 08; 11(8):1305-1310.
View in:
PubMed
AMP-Activated Protein Kinase Directly Phosphorylates and Destabilizes Hedgehog Pathway Transcription Factor GLI1 in Medulloblastoma. Cell Rep. 2015 Jul 28; 12(4):599-609.
View in:
PubMed
Symptoms and palliative care needs of pancreatic adenocarcinoma patients. J Palliat Med. 2014 Jun; 17(6):640-1.
View in:
PubMed